​

Pacira BioSciences (PCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PCRX Stock Forecast

Pacira BioSciences stock forecast is as follows: an average price target of $23.75 (represents a 19.77% upside from PCRX’s last price of $19.83) and a rating consensus of 'Hold', based on 8 wall street analysts offering a 1-year stock forecast.

PCRX Price Target

The average price target for Pacira BioSciences (PCRX) is $23.75 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $57.00 to $8.00. This represents a potential 19.77% upside from PCRX's last price of $19.83.

PCRX Analyst Ratings

Hold

According to 8 Wall Street analysts, Pacira BioSciences's rating consensus is 'Hold'. The analyst rating breakdown for PCRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (37.50%), 5 'Hold' (62.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Pacira BioSciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024David AmsellemPiper Sandler$12.00$17.36-30.90%-39.49%
Sep 24, 2024Glen SantangeloJefferies$18.00$14.7721.87%-9.23%
Aug 13, 2024Les SulewskiTruist Financial$8.00$12.29-34.91%-59.66%
Jul 02, 2024Oren LivnatH.C. Wainwright$57.00$21.91160.16%187.44%
Jun 13, 2024Glen SantangeloJefferies$36.00$28.5026.32%81.54%
May 21, 2024David AmsellemPiper Sandler$42.00$30.6836.88%111.80%
Jan 06, 2023BMO Capital$52.00$38.5035.06%162.23%
Jan 06, 2023Needham$63.00$38.5063.64%217.70%

The latest Pacira BioSciences stock forecast, released on Nov 07, 2024 by David Amsellem from Piper Sandler, set a price target of $12.00, which represents a -30.90% decrease from the stock price at the time of the forecast ($17.36), and a -39.49% decrease from PCRX last price ($19.83).

Pacira BioSciences Price Target by Period

1M3M12M
# Anlaysts-26
Avg Price Target-$15.00$28.83
Last Closing Price$19.83$19.83$19.83
Upside/Downside-100.00%-24.36%45.39%

In the current month, the average price target of Pacira BioSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pacira BioSciences's last price of $19.83. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 07, 2024Piper SandlerNeutralNeutralHold
Sep 24, 2024Truist FinancialSector PerformSector PerformHold
Sep 24, 2024RBC CapitalUnderperformUnderperformHold
Sep 24, 2024JefferiesBuyBuyHold
Aug 12, 2024RBC CapitalSector PerformSector PerformHold
Aug 12, 2024RBC CapitalUnderperformSector PerformDowngrade
Aug 12, 2024Raymond JamesUnderperformMarket PerformDowngrade
Aug 12, 2024Piper SandlerBuyNeutralDowngrade
Jul 25, 2024Piper SandlerBuyBuyHold
Jul 25, 2024NeedhamUnderperformUnderperformHold
Jul 03, 2024BarclaysEqual-WeightDowngrade
Jul 02, 2024NeedhamBuyBuyHold
Jul 02, 2024H.C. WainwrightUnderperformUnderperformHold
Jul 02, 2024H.C. WainwrightBuyBuyHold
Jun 13, 2024JefferiesBuyBuyHold
May 21, 2024Piper SandlerOverweightOverweightHold
Apr 09, 2024WedbushBuyBuyHold
Apr 09, 2024RBC CapitalUnderperformUnderperformHold
Mar 01, 2024RBC CapitalUnderperformUnderperformHold
Mar 01, 2024WedbushBuyBuyHold
Dec 20, 2023RBC CapitalBuyBuyHold
Dec 20, 2023Raymond JamesUnderperformUnderperformHold
Aug 03, 2023Cowen & Co.OutperformUpgrade
Jan 06, 2023BMO CapitalMarket PerformMarket PerformHold
Jan 06, 2023NeedhamBuyBuyHold
Jun 15, 2022NeedhamBuyBuyHold
Feb 28, 2022WedbushOutperformOutperformHold

Pacira BioSciences's last stock rating was published by Piper Sandler on Nov 07, 2024. The company gave PCRX a "Neutral" rating, the same as its previous rate.

Pacira BioSciences Financial Forecast

Pacira BioSciences Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$181.24M$163.93M$169.47M$160.34M$171.96M$167.47M$169.41M$157.99M$159.19M$127.72M$135.59M$119.03M$130.97M$117.48M$75.50M$105.68M$122.42M$104.69M$102.60M$91.31M$74.61M$69.28M
Avg Forecast$158.28M$152.05M$161.49M$161.92M$180.22M$169.55M$173.70M$165.32M$180.62M$172.95M$174.85M$159.19M$171.94M$168.33M$170.64M$159.72M$156.29M$129.42M$132.48M$119.31M$131.66M$116.13M$72.08M$101.68M$121.22M$105.02M$100.43M$92.36M$74.61M$14.59M
High Forecast$170.66M$163.94M$174.12M$178.37M$186.49M$169.91M$173.70M$165.32M$181.23M$173.18M$188.53M$171.63M$185.39M$168.33M$170.64M$159.72M$156.29M$129.42M$132.48M$119.31M$131.66M$116.13M$72.08M$101.68M$121.22M$105.02M$100.43M$92.36M$89.53M$17.50M
Low Forecast$142.03M$136.44M$144.91M$140.34M$170.75M$169.19M$173.70M$165.32M$179.71M$172.71M$156.90M$142.84M$154.28M$168.33M$170.64M$159.72M$156.29M$129.42M$132.48M$119.31M$131.66M$116.13M$72.08M$101.68M$121.22M$105.02M$100.43M$92.36M$59.69M$11.67M
# Analysts1113733475632222345613889127781612
Surprise %--------1.00%0.95%0.97%1.01%1.00%0.99%0.99%0.99%1.02%0.99%1.02%1.00%0.99%1.01%1.05%1.04%1.01%1.00%1.02%0.99%1.00%4.75%

Pacira BioSciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $165.32M, with a low forecast of $165.32M, and a high forecast of $165.32M. PCRX's average Quarter revenue forecast represents a -8.79% decrease compared to the company's last Quarter revenue of $181.24M (Dec 23).

Pacira BioSciences EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113733475632222345613889127781612
EBITDA--------$33.17M$17.72M$39.88M$26.47M$31.43M$31.71M$32.77M$40.73M$16.52M$36.63M$36.91M$23.89M$24.17M$17.69M$2.69M$18.96M$7.11M$5.30M$11.86M$6.48M$-3.13M$-14.34M
Avg Forecast$30.72M$29.51M$31.34M$31.42M$34.98M$32.91M$33.71M$54.12M$35.05M$33.57M$33.94M$49.20M$16.76M$32.10M$32.54M$44.73M$29.81M$24.68M$25.26M$28.00M$25.11M$22.15M$13.75M$16.03M$23.12M$20.03M$19.15M$7.47M$-3.13M$-35.50M
High Forecast$33.12M$31.82M$33.79M$34.62M$36.19M$32.97M$33.71M$64.94M$35.17M$33.61M$36.59M$59.04M$20.11M$32.10M$32.54M$53.67M$29.81M$24.68M$25.26M$33.60M$25.11M$22.15M$13.75M$19.24M$23.12M$20.03M$19.15M$8.97M$-2.50M$-28.40M
Low Forecast$27.56M$26.48M$28.12M$27.24M$33.14M$32.84M$33.71M$43.29M$34.88M$33.52M$30.45M$39.36M$13.40M$32.10M$32.54M$35.78M$29.81M$24.68M$25.26M$22.40M$25.11M$22.15M$13.75M$12.83M$23.12M$20.03M$19.15M$5.98M$-3.75M$-42.60M
Surprise %--------0.95%0.53%1.18%0.54%1.88%0.99%1.01%0.91%0.55%1.48%1.46%0.85%0.96%0.80%0.20%1.18%0.31%0.26%0.62%0.87%1.00%0.40%

4 analysts predict PCRX's average Quarter EBITDA for Mar 24 to be $54.12M, with a high of $64.94M and a low of $43.29M. This is 63.16% upper than Pacira BioSciences's previous annual EBITDA (Dec 23) of $33.17M.

Pacira BioSciences Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113733475632222345613889127781612
Net Income--------$24.87M$22.34M$25.76M$-19.54M$-10.10M$-693.00K$19.88M$6.83M$-5.13M$17.66M$19.08M$10.37M$14.52M$130.12M$-7.27M$8.16M$-4.89M$-6.09M$2.73M$-2.77M$-10.68M$-19.87M
Avg Forecast$33.46M$31.16M$32.83M$29.60M$36.30M$32.50M$32.24M$10.15M$40.75M$36.01M$35.00M$9.23M$-5.20M$38.74M$43.07M$8.39M$45.64M$32.85M$35.67M$12.15M$41.69M$32.92M$4.69M$6.90M$22.18M$16.46M$17.49M$-3.20M$-10.68M$-49.17M
High Forecast$36.86M$34.32M$36.17M$31.88M$40.28M$32.97M$32.25M$12.18M$44.87M$36.12M$38.56M$11.08M$-4.16M$38.74M$43.07M$10.07M$45.64M$32.85M$35.67M$14.58M$41.69M$32.92M$4.69M$8.28M$22.18M$16.46M$17.49M$-2.56M$-8.54M$-39.33M
Low Forecast$28.99M$27.00M$28.45M$27.70M$33.64M$32.03M$32.24M$8.12M$37.54M$35.91M$30.33M$7.38M$-6.24M$38.74M$43.07M$6.71M$45.64M$32.85M$35.67M$9.72M$41.69M$32.92M$4.69M$5.52M$22.18M$16.46M$17.49M$-3.84M$-12.82M$-59.00M
Surprise %--------0.61%0.62%0.74%-2.12%1.94%-0.02%0.46%0.81%-0.11%0.54%0.53%0.85%0.35%3.95%-1.55%1.18%-0.22%-0.37%0.16%0.87%1.00%0.40%

Pacira BioSciences's average Quarter net income forecast for Mar 24 is $10.15M, with a range of $8.12M to $12.18M. PCRX's average Quarter net income forecast represents a -59.18% decrease compared to the company's last Quarter net income of $24.87M (Dec 23).

Pacira BioSciences SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113733475632222345613889127781612
SG&A--------$65.80M$67.95M$64.85M$70.84M$63.97M$61.28M$65.00M$64.26M$51.20M$48.81M$50.81M$48.52M$52.83M$52.56M$43.34M$44.78M$54.22M$50.13M$49.13M$48.52M$44.19M$42.12M
Avg Forecast$66.03M$63.43M$67.37M$67.54M$75.18M$70.73M$72.46M$95.55M$75.34M$72.14M$72.94M$86.87M$51.94M$70.22M$71.18M$78.97M$65.20M$53.99M$55.26M$56.86M$54.92M$48.44M$30.07M$37.87M$50.57M$43.81M$41.89M$55.98M$44.19M$6.08M
High Forecast$71.19M$68.39M$72.63M$74.41M$77.79M$70.87M$72.46M$114.66M$75.60M$72.24M$78.64M$104.24M$62.33M$70.22M$71.18M$94.76M$65.20M$53.99M$55.26M$68.23M$54.92M$48.44M$30.07M$45.44M$50.57M$43.81M$41.89M$67.18M$53.03M$7.30M
Low Forecast$59.24M$56.91M$60.45M$58.54M$71.23M$70.58M$72.46M$76.44M$74.96M$72.05M$65.45M$69.49M$41.55M$70.22M$71.18M$63.18M$65.20M$53.99M$55.26M$45.49M$54.92M$48.44M$30.07M$30.29M$50.57M$43.81M$41.89M$44.79M$35.35M$4.87M
Surprise %--------0.87%0.94%0.89%0.82%1.23%0.87%0.91%0.81%0.79%0.90%0.92%0.85%0.96%1.09%1.44%1.18%1.07%1.14%1.17%0.87%1.00%6.92%

Pacira BioSciences's average Quarter SG&A projection for Mar 24 is $95.55M, based on 4 Wall Street analysts, with a range of $76.44M to $114.66M. The forecast indicates a 45.22% rise compared to PCRX last annual SG&A of $65.80M (Dec 23).

Pacira BioSciences EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113733475632222345613889127781612
EPS--------$0.48$0.48$0.56$-0.43$-0.22$-0.02$0.44$0.15$-0.12$0.40$0.43$0.24$0.33$3.03$-0.17$0.19$-0.12$-0.15$0.07$-0.07$-0.26$-0.52
Avg Forecast$0.73$0.68$0.71$0.64$0.79$0.70$0.70$0.62$0.88$0.78$0.76$0.62$0.83$0.77$0.85$0.83$0.90$0.65$0.71$0.64$0.82$0.65$0.09$0.30$0.44$0.33$0.35$0.26$0.02$-0.10
High Forecast$0.80$0.74$0.78$0.69$0.87$0.71$0.70$0.62$0.97$0.78$0.84$0.68$0.91$0.77$0.85$0.83$0.90$0.65$0.71$0.64$0.82$0.65$0.09$0.30$0.44$0.33$0.35$0.26$0.02$-0.08
Low Forecast$0.63$0.59$0.62$0.60$0.73$0.69$0.70$0.62$0.81$0.78$0.66$0.53$0.72$0.77$0.85$0.83$0.90$0.65$0.71$0.64$0.82$0.65$0.09$0.30$0.44$0.33$0.35$0.26$0.02$-0.12
Surprise %--------0.54%0.61%0.74%-0.70%-0.27%-0.02%0.52%0.18%-0.13%0.62%0.61%0.38%0.40%4.65%-1.83%0.64%-0.27%-0.46%0.20%-0.27%-13.00%5.20%

According to 4 Wall Street analysts, Pacira BioSciences's projected average Quarter EPS for Mar 24 is $0.62, with a low estimate of $0.62 and a high estimate of $0.62. This represents a 29.19% increase compared to PCRX previous annual EPS of $0.48 (Dec 23).

Pacira BioSciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ANIPANI Pharmaceuticals$55.83$79.0041.50%Buy
COLLCollegium Pharmaceutical$30.90$42.3336.99%Buy
ALKSAlkermes$30.75$37.5021.95%Hold
PCRXPacira BioSciences$19.83$23.7519.77%Hold
HCMHUTCHMED (China)$14.86$17.5017.77%Buy
PBHPrestige Consumer Healthcare$80.39$89.5011.33%Buy
ITCIIntra-Cellular Therapies$86.96$93.337.33%Buy
PAHCPhibro Animal Health$22.34$18.67-16.43%Buy

PCRX Forecast FAQ

Is Pacira BioSciences a good buy?

No, according to 8 Wall Street analysts, Pacira BioSciences (PCRX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 37.50% of PCRX's total ratings.

What is PCRX's price target?

Pacira BioSciences (PCRX) average price target is $23.75 with a range of $8 to $57, implying a 19.77% from its last price of $19.83. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pacira BioSciences stock go up soon?

According to Wall Street analysts' prediction for PCRX stock, the company can go up by 19.77% (from the last price of $19.83 to the average price target of $23.75), up by 187.44% based on the highest stock price target, and down by -59.66% based on the lowest stock price target.

Can Pacira BioSciences stock reach $30?

PCRX's highest twelve months analyst stock price target of $57 supports the claim that Pacira BioSciences can reach $30 in the near future.

What are Pacira BioSciences's analysts' financial forecasts?

Pacira BioSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $688.79M (high $695.42M, low $678.96M), average EBITDA is $155.71M (high $167.82M, low $142.98M), average net income is $111.2M (high $117.69M, low $106.03M), average SG&A $313.91M (high $335.79M, low $290.7M), and average EPS is $2.81 (high $2.91, low $2.74). PCRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $633.74M (high $687.09M, low $563.71M), average EBITDA is $122.99M (high $133.35M, low $109.4M), average net income is $127.05M (high $139.24M, low $112.14M), average SG&A $264.36M (high $286.62M, low $235.15M), and average EPS is $2.75 (high $3.02, low $2.43).

Did the PCRX's actual financial results beat the analysts' financial forecasts?

Based on Pacira BioSciences's last annual report (Dec 2023), the company's revenue was $674.98M, which missed the average analysts forecast of $687.61M by -1.84%. Apple's EBITDA was $87.68M, missing the average prediction of $151.75M by -42.22%. The company's net income was $41.96M, missing the average estimation of $121M by -65.33%. Apple's SG&A was $269.44M, missing the average forecast of $307.29M by -12.32%. Lastly, the company's EPS was $0.81, missing the average prediction of $3.04 by -73.35%. In terms of the last quarterly report (Dec 2023), Pacira BioSciences's revenue was $181.24M, beating the average analysts' forecast of $180.62M by 0.35%. The company's EBITDA was $33.17M, missing the average prediction of $35.05M by -5.38%. Pacira BioSciences's net income was $24.87M, missing the average estimation of $40.75M by -38.97%. The company's SG&A was $65.8M, missing the average forecast of $75.34M by -12.67%. Lastly, the company's EPS was $0.48, missing the average prediction of $0.883 by -45.66%